[HTML][HTML] Radiopharmaceutical therapy in cancer: clinical advances and challenges
Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …
[HTML][HTML] Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
V Ambrosini, J Kunikowska, E Baudin, L Bodei… - European journal of …, 2021 - Elsevier
Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of …
Purpose Diverse radionuclide imaging techniques are available for the diagnosis, staging,
and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to …
and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to …
Targeted α-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical …
ES Delpassand, I Tworowska… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Peptide receptor radiotherapy with somatostatin analogs has been successfully used for
years as a treatment for somatostatin-overexpressing tumors. Treatment of neuroendocrine …
years as a treatment for somatostatin-overexpressing tumors. Treatment of neuroendocrine …
[HTML][HTML] Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future
AK Stueven, A Kayser, C Wetz, H Amthauer… - International journal of …, 2019 - mdpi.com
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased.
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …
Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases …
Nanoparticles for cancer diagnosis, radionuclide therapy and theranostics
J Llop, T Lammers - ACS nano, 2021 - ACS Publications
Nanoparticles have unique properties that can be exploited for cancer diagnosis and
therapy. Intravenously injected nanoparticles accumulate predominantly in organs of the …
therapy. Intravenously injected nanoparticles accumulate predominantly in organs of the …
[HTML][HTML] Somatostatin receptor PET ligands-the next generation for clinical practice
Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …
[HTML][HTML] Overview of radiolabeled somatostatin analogs for cancer imaging and therapy
R Eychenne, C Bouvry, M Bourgeois, P Loyer… - Molecules, 2020 - mdpi.com
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
Radiolabeled peptides and antibodies in medicine
P Kręcisz, K Czarnecka, L Królicki… - Bioconjugate …, 2020 - ACS Publications
Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still
expanding. This group is very diverse in terms of peptide size. It contains very small …
expanding. This group is very diverse in terms of peptide size. It contains very small …
First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms …
The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …